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ABSTRACT
Maize ribosome-inactivating protein (RIP) is a plant
toxin that inactivates eukaryotic ribosomes by
depurinating a specific adenine residue at the
a-sarcin/ricin loop of 28S rRNA. Maize RIP is first
produced as a proenzyme with a 25-amino acid
internal inactivation region on the protein surface.
During germination, proteolytic removal of this
internal inactivation region generates the active
heterodimeric maize RIP with full N-glycosidase
activity. This naturally occurring switch-on
mechanism provides an opportunity for targeting
the cytotoxin to pathogen-infected cells. Here, we
report the addition of HIV-1 protease recognition
sequences to the internal inactivation region and
the activation of the maize RIP variants by HIV-1
protease in vitro and in HIV-infected cells. Among
the variants generated, two were cleaved efficiently
by HIV-1 protease. The HIV-1 protease-activated
variants showed enhanced N-glycosidase activity
in vivo as compared to their un-activated counter-
parts. They also possessed potent inhibitory effect
on p24 antigen production in human T cells infected
by two HIV-1 strains. This switch-on strategy for
activating the enzymatic activity of maize RIP in
target cells provides a platform for combating
pathogens with a specific protease.
INTRODUCTION
Ribosome-inactivating proteins (RIPs) are RNA
N-glycosidases which cleave the N-glycosidic bond of
adenine-4324 at the a-sarcin/ricin (SR) loop of 28S
rRNA. The depurination of the SR loop results in the
inhibition of protein synthesis by impairing the binding
of EF-1 or EF-2 to the ribosomes, hence the high cytotox-
icity of RIPs. Maize RIP is classiﬁed as a type III RIP. It is
synthesized in the endosperm of maize as an inactive pre-
cursor, which contains a 25 amino acid internal inactiva-
tion region, 16 aa at the N-terminus and 14 aa at the
C-terminus. During germination, a two-chain activated
form is generated by endogenous proteolysis of the
internal inactivation region, along with the removal of
the N- and the C-terminal sequences. The two chains
(16.5 and 8.5kDa) are tightly associated without disulﬁde
linkage. It has been shown that a variant (MOD) with the
two chains fused through a 2 aa linker possessed protein
inhibitory activity similar to that of the native two-chain
form (1–3). Our group has solved the crystal structures of
both MOD and a construct Pro-RIP which contains the
25 aa internal inactivation region but with the 16 aa
N-terminal and 14 aa C-terminal sequences removed.
We found that this internal inactivation region (Ala163–
Asp189) is located on the surface of the N-terminal
domain in Pro-RIP (4). The secondary structural
elements of the crystal structure of MOD and its
solution structure by nuclear magnetic resonance
(NMR) spectrometry are comparable and most a-helices
and b-strands are similar in length (5). Although maize
RIP only has about 20% sequence homology with other
type I and II RIPs, their N-glycosidase domains are
similar and the active site residues including Tyr94,
Tyr130, Glu207, Arg210 and Trp241 at the cleft between
the N- and C-terminal are conserved (4–6). The presence
of the internal inactivation region of maize RIP led us to
derive a novel strategy to enhance the speciﬁcity of maize
RIP towards target cells expressing a speciﬁc protease.
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abortiﬁciant (7,8), anti-cancer (9–11) and anti-HIV
agents (12–17), either alone or as a component of
immunotoxins (18,19). Many type I and II RIPs, such as
MAP30, GAP30, DAP30, pokeweed antiviral protein
(PAP) and ricin, have been reported to possess anti-HIV
activity by inhibiting viral replication in vitro and in vivo
(13,14,20–23), although the anti-HIV mechanism is still
unclear. As a test case for increasing the speciﬁcity of
maize RIP towards cells expressing a speciﬁc protease,
we provide an account on the generation of HIV-1
protease-sensitive maize RIP by incorporating the HIV-1
protease recognition sequences to the internal inactivation
region of the Pro-RIP (Figure 1). Several variants were
constructed and two were found to be cleaved and
activated by recombinant HIV-1 protease in vitro and in
HIV-infected cells, resulting in an active two-chain form
with N-glycosidase activity comparable to the fully active
maize RIP. In addition, the variants inhibited viral repli-
cation in human T lymphocytes infected by two T-tropic
HIV-1 strains, and their cytotoxicity towards uninfected
cells was similar to the unactivated precursors.
MATERIALS AND METHODS
Construction, expression and puriﬁcation of proteins
Maize [1–16, 287–300]-Pro-RIP (Pro-RIP-WT) and
[1–16, 163–164, 167–189, 287–300]-Pro-RIP
(MOD-WT) were provided by Prof. R.S. Boston.
Pro-HIV-MA/CA-16, Pro-HIV-MA/CA-20, Pro-HIV-
MA/CA, N-terminal TAT-fusion variants TAT-Pro-RIP,
TAT-MOD, TAT-Pro-HIV-MA/CA-3aa, TAT-Pro-
HIV-MA/CA-2aa, TAT-Pro-HIV-MA/CA and TAT-
Pro-HIV-p2/NC were generated by polymerase chain
reaction mutagenesis using overlapping primers and
Phusion DNA polymerase (Finnzymes, Woburn, MA,
USA). DNA were cloned into expression vector pET3a
and sequenced to conﬁrm that no secondary mutation
had occurred. Proteins were over-expressed in
Escherichia coli strain C41 (DE3) from Novagen (EMD
Chemicals Inc., Gibbstown, NJ, USA) in LB medium.
Bacterial cells were grown in 37 C until OD600
reached 0.4–0.6 and 0.4mM isopropyl b-D-1-thiogalacto-
pyranoside (IPTG) was added to induce protein expression
at 25 C. The cells were harvested after overnight culture by
Figure 1. Schematic diagram of the maize RIP and recombinant variants. (A) The artiﬁcial construct maize RIP precursor Pro-RIP (Pro-RIP)
contains the 25 aa internal inactivation region but without the 16 aa N-terminal and 14 aa C-terminal sequences of the inactive maize RIP precursor.
The amino acid sequence of the internal inactivation region is shown. Cleavage sites leading to the generation of the active two-chain maize RIP are
indicated by inverted ﬁlled triangles. MOD is another artiﬁcial construct with the two polypeptides fused by an Leu-Glu bipeptide. (B) The internal
inactivation region was replaced by HIV-1 protease recognition site. Pro-HIV-MA/CA: the ﬁrst and last 10 aa of the internal inactivation region
were replaced by the 10 aa MA/CA site. Pro-HIV-MA/CA-20: two 10 aa MA/CA sites were introduced to the internal inactivation region.
Pro-HIV-MA/CA-16: the whole internal inactivation region was replaced by one copy of MA/CA site followed by a hexapeptide of AAAAAD.
(C) TAT-Pro and TAT-MOD: A Tat sequence was fused to the N-termini of Pro-RIP and MOD, respectively. (D) TAT-Pro-HIV-p2/NC and
TAT-Pro-HIV-MA/CA: TAT-Pro with the ﬁrst and last 10 aa replaced by the p2/NC site (TATIM/MQRGN) and the MA/CA site (VSQNY/
PIVQN), respectively. (E) TAT-Pro-HIV-MA/CA-2aa and TAT-Pro-HIV-MA/CA-3aa: the recognition sequence of the MA/CA site was shortened
to reduce the number of aa left to 2 and 3, respectively, after cleavage. The underlined sequences are the recognition sites of HIV-1 protease and #
indicates the HIV-1 protease cleavage site.
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pellet was resuspended and sonicated in 20mM sodium
phosphate buﬀer, pH 7.0. After centrifugation at 4 C,
the supernatant was loaded to a HiTrap CM-FF column
(5ml; GE Healthcare). Protein was eluted using a linear
gradient of 0–1M NaCl in 20mM sodium phosphate
buﬀer, pH 7.0. The target fractions were pooled and then
loaded onto a HiTrap SP XL column (5ml; GE
Healthcare). Elution was done by using a linear gradient
0–1M NaCl in 20mM sodium phosphate buﬀer, pH 7.0.
For TAT-fused proteins, cell pellet was resuspended and
sonicated in 50mM sodium acetate buﬀer, 100mM NaCl
and 8M urea, pH 5.5 (Buﬀer A). The cell lysate was
centrifuged at 4 C and the supernatant was loaded onto
a HiTrap SP FF column (5ml; GE Healthcare)
pre-equilibrated with buﬀer A. Protein was eluted using a
gradient of 0–1M NaCl in 50mM sodium acetate buﬀer,
pH 5.5. Fractions containing the target protein were
pooled and dialyzed against 50mM sodium acetate
buﬀer, 100mM NaCl, 4M urea, pH 5.5 (Buﬀer C) and
loaded onto a HiTrap SP XL column (5ml; GE
Healthcare) pre-equilibrated with buﬀer C. Proteins were
eluted using a linear gradient of 0–1M NaCl in 50mM
sodium acetate buﬀer, pH 5.5. Target fractions were
pooled and concentrated to 5ml for further puriﬁcation
by a HiPrep 26/10 desalting column (GE Healthcare)
pre-equilibrated with 10mM Tris–HCl, 1mM EDTA,
10% glycerol, pH 7.0. The puriﬁed protein was
concentrated and stored at  70 C.
HIV-1 protease expression and puriﬁcation
A plasmid containing the open reading frame of HIV-1
protease was provided by Prof. C.C. Wan. HIV-1 protease
was then cloned into expression vector pET3b and used to
transform E. coli BL21 (DE3) pLysS. A single colony was
inoculated to 1l of LB broth containing 100mg/ml of
ampicillin and chloramphenicol, respectively. The bacter-
ial culture was incubated at 37 C with shaking at
250r.p.m., until OD600 reached 0.3–0.5 and 0.4mM
IPTG was added to induce protein expression at 37 C
for 4h. HIV-1 protease was expressed as inclusion
bodies and was puriﬁed as described (24).
Puriﬁcation of HIV-1 protease-cleaved maize
RIP variants
Puriﬁed TAT-Pro-HIV-MA/CA and TAT-Pro-HIV-p2/
NC (100mM) were incubated with recombinant HIV-1
protease (0.5mg) in 50mM sodium acetate buﬀer (pH
5.5) at 37 C for 16h to remove the internal inactivation
region. HIV-1 protease was then isolated from the
activated variants by gel ﬁltration chromatography using
Superdex 75 column (GE Healthcare) which was
pre-equilibrated with 10mM Tris–HCl, 1mM EDTA,
10% glycerol, pH 7.0. The puriﬁed variants were
concentrated and stored at  70 C.
Virus and cell lines
Human T lymphocyte cell line (C8166) was obtained from
Medical Research Council, AIDS Reagent Project, UK
and maintained in RPMI-1640 medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS). Mouse macrophage cells (J774A.1)
were purchased from American Type Culture Collection
(ATCC; Manassas, VA, USA) and cultured in Dulbecco’s
modiﬁed Eagle’s medium (Invitrogen) with 10% FBS.
HIV-1IIIB and HIV-1 RF/V82F/I84V were obtained
from the culture supernatant of H9/HIV-1IIIB and
MT-2/HIV-1 RF/V82F/I84V cells, respectively. The 50%
HIV-1 tissue culture infection dose (TCID50) in C8166
cells was determined and calculated by the Reed and
Muench method (25). Virus stocks were stored in
aliquots at  70 C. The titre of the virus stock was
3.4 10
6 TCID50 per millilitre (26).
N-glycosidase activity assay
Human T lymphocytes (C8166) and mouse macrophage
cells (J774A.1; 1 10
6 per dish) were plated in tissue
culture dishes (60 15mm). Protein samples (5mM) were
added and incubated for 6h. After incubation, culture
medium was removed and the cells were washed twice
by ice-cold PBS.
RNA was isolated from the treated cells using the
modiﬁed TRIZOL RNA isolation protocol (27). RNA
was dissolved in diethypyrocarbonate (DEPC) water and
stored at  80 C and reverse-transcribed using SuperScript
II Reverse Transcriptase kit (Invitrogen). RNA samples
(5mg) were prepared to a ﬁnal volume of 11ml and
cDNA was synthesized at 42 C for 50min in a ﬁnal
volume of 20ml using 1ml of Superscript II reverse tran-
scriptase (200U/ml). The cDNA samples were stored at
 20 C.
Quantitative real-time PCR (qRT-PCR) was performed
using a 7500 Fast Real-Time PCR System (Applied
Biosystems) with Power SYBR Green PCR Master Mix
kit (Applied Biosystems). The 20ml reaction contained 1ml
of cDNA sample which was diluted by 100-fold from
the reverse transcription reaction. Published primers
were used to quantify the total 28S rRNA (control)—
forward primer 50-GATGTCGGCTCTTCCTATCATTG
T-30 and reverse primer 50-CCAGCTCACGTTCCCTAT
TAGTG-30; and deadenylated rRNA (test)—forward
primer 50-TGCCATGGTAATCCTGCTCAGTA-30 and
reverse primer 50-TCTGAACCTGCGGTTCCACA-30
(28). Ampliﬁcation conditions were as follows: 1 cycle at
95 C for 5min followed by 40 cycles at 95 C for 10sec and
at 60 C for 30sec. Each cDNA sample was run in dupli-
cation with both primer sets. Sequence Detection Software
for the 7500 Fast System was used for data collection and
threshold cycle (CT) examination. Data manipulations
were carried out using Prism (GraphPad Software, Inc.,
La Jolla, CA, USA). The CT value of each run was con-
verted to the amount of nucleic acid (2
 CT). The relative
amount of altered rRNA was calculated as the amount of
nucleic acid determined by the test primers divided by the
amount determined by the control primers. The relative
N-glycosidase activity was calculated as the relative
amount of altered rRNA of sample-treated cells over the
untreated cells. Mean±SEM was calculated for the
graphic presentation. Unpaired t-test was performed for
statistical analysis.
Nucleic Acids Research, 2010,Vol.38, No. 19 6805Cytotoxicity assay
Cell viability was evaluated by a colorimetric method
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide,
MTT assay) (29). Human T cells (C8166) were
proliferated at log phase in RPMI-1640 medium supple-
mented with 10% FBS before seeded on 96 well plates
(3 10
4 cell/ well, 100ml). Six diﬀerent concentration of
proteins were diluted in 100ml RPMI-1640 medium with
10% FBS and then added into the wells. After
incubating at 37 C for 72h in 5% CO2, cells were
exposed to MTT (5mg/ml) for 4h. To dissolve the
purple formazan, 100ml of 50% dimethylformamide
and 10% SDS was added. OD595/630 values were
measured using Bio-Tek ELx 800 ELISA reader. The
cell viability after treatment with diﬀerent proteins was
presented in percentage to control as mean±SD and
two-way ANOVA with Bonferroni test as the post hoc
test for multiple comparison was used.
Detection of the removal of the inactivation loop
Puriﬁed protein samples (100mM) were incubated with
recombinant HIV-1 protease (0.5mg) in 50mM sodium
acetate buﬀer (pH 5.5) at 37 C. Aliquot (5ml) was col-
lected after a 24h incubation. The reactions were
stopped by adding 5 loading buﬀer and heating at
95 C for 5min. Proteins of each reaction were analysed
by SDS-PAGE. To detect cleavage of the internal inacti-
vation region in HIV-infected cells, HIV-1IIIB acutely
infected human C8166 cells (1 10
6/ml) were incubated
with maize RIP variants (0.2mg/ml) at 37 C for 72h
before the isolation of cytoplasmic proteins. The cells
were washed thoroughly with 5ml ice-cold PBS twice
before trypsinized at 37 C for 10min. Cell pellets were
then washed with 5ml ice-cold PBS and then resuspended
and lysed in 200ml modiﬁed RIPA buﬀer (20mM Tris–
HCl, pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA,
1% NP40, 1% sodium deoxycholate and 1mM Na3VO4)
with 1mM PMSF. Cytoplasmic proteins were isolated
from cell debris by centrifugation at 13000r.p.m., 4 C
for 15min. Supernatant (10ml) was collected for western
blot analysis. In brief, the resolved proteins were
transferred from gel to polyvinylidene diﬂuoride
membrane by semi-dry transfer at 10 mA for 30min in
transfer buﬀer. The membrane was immediately placed
into blocking buﬀer (5% non-fat dry milk, 10mM Tris
pH 7.5, 100mM NaCl and 0.1% Tween 20). Anti-MOD
polyclonal antibody was diluted 1:10000 in 5ml blocking
buﬀer and incubated with the membrane overnight at 4 C.
The membrane was then washed with wash buﬀer
(1 TBS buﬀer with 0.1% Tween 20) for three times.
The secondary antibody (anti-rabbit IgG; Santa Cruz
Biotechnology, Inc.) was diluted 1:5000 and incubated
with agitation with the membrane at room temperature
for 1hr. Protein bands were detected by chemiluminescent
(Amersham ECL western blotting detection reagents and
analysis system, GE Healthcare). The blot was exposed to
X-ray ﬁlm (Super HR-T 30, Fujiﬁlm) for 15–60sec and the
ﬁlm was then developed.
Syncytium reduction assay
C8166 cells (3 10
4 cells/well) were seeded and inoculated
with 100 TCID50 HIV-1IIIB or HIV-1 RF/V82F/I84V. Six
diﬀerent concentration of protein samples in 100ml
RPMI-1640 medium with 10% FBS were added to the
cells and then incubated at 37 C in a humidiﬁed incubator
with 5% CO2 for 72h. Control experiment was performed
without the tested protein in HIV-1-infected and -unin-
fected cultures. The number of syncytia in each well was
counted under microscope. Percentage inhibition of syn-
cytial cell formation was calculated from the syncytial cell
number in treated culture versus that from the uninfected
control culture (26). Two-way ANOVA with Bonferroni
test as the post hoc test for multiple comparison was used
for statistical analysis.
ELISA for HIV-1 p24 antigen
HIV-1 p24 antigen in cell-free medium was measured
using capture ELISA as described previously (30).
Brieﬂy, 96 well plates were coated with McAb p5F1
followed by blocking with 5% skim milk. Then, Triton
X-100-treated cell-free culture medium was added and
incubated at 37 C for 2h. The plates were then incuba-
ted with diluted human polyclonal anti-HIV-1 sera,
followed by HRP-labelled goat anti-human IgG and
o-phenylenediamine dihydrochloride (OPD) substrate.
The plates were read by Bio-Tek ELx 800 ELISA reader
at 490/630nm within 30min after the reaction. The inhib-
ition percentage of p24 antigen expression was calculated
in comparison with the uninfected control culture.
Two-way ANOVA with Bonferroni test as the post hoc
test for multiple comparison was used for statistical
analysis. The concentration of protein that caused a re-
duction of p24 antigen expression by 50% (EC50) was
determined from the dose-response curve.
RESULTS
Speciﬁc cleavage of HIV-1 protease-sensitive maize RIP
variants in vitro and in HIV-infected cells
The HIV-1 protease cleavage sequences TATIM/
MQRGN (p2/NC site) and VSQNY/PIVQN (MA/CA
site) located in the polyprotein precursor Gag of HIV-1
(31) were selected based on their high kcat/Km values
towards HIV-1 protease (32,33). We ﬁrst replaced the
whole internal inactivation region by two consecutive
MA/CA sites. However, the variant Pro-HIV-MA/
CA-20 could only be partially cleaved by HIV-1
protease (Figures 1B and 2A). Shortening the internal
inactivation region by changing the C-terminal MA/CA
site to a hexapeptide AAAAAD resulted in an
uncleavable variant (Pro-RIP-MA/CA-16; Figures 1B
and 2A). We then kept the length of the internal inacti-
vation region (25 aa) and replaced the ﬁrst and the last
10 aa with the MA/CA site (Figure 1B). This
Pro-RIP-MA/CA variant was cleaved completely by
HIV-1 protease into two target bands ( 11kDa and
17kDa) in 16h at 37 C (Figure 2A).
6806 Nucleic Acids Research, 2010,Vol.38, No. 19To promote cell entry, an 11 aa transduction peptide
YGRKKRRQRRR derived from the HIV-1 Tat protein
was fused to the N-termini of Pro-RIP and MOD to
generate TAT-Pro and TAT-MOD, respectively
(Figure 1C). The two TAT-fused maize RIP variants
TAT-Pro-HIV-p2/NC and TAT-Pro-HIV-MA/CA with
the substitution of HIV-1 protease recognition sequences
TATIM/MQRGN (p2/NC site) and VSQNY/PIVQN
(MA/CA site), respectively, in the 25 aa internal inactiva-
tion region (Figure 1D) were cleaved by HIV-1 protease
under the same conditions of the non-TAT variants
(Figure 2B). Thus, fusion of the TAT transduction
peptide did not aﬀect the cleavage eﬃciency in vitro.I n
addition, western blot analysis indicated that these
TAT-fused variants were also cleaved inside the
HIV-1IIIB acutely infected C8166 cells (Figure 2C). No
detectable proteolytic cleavage by HIV-1 protease was
observed for TAT-Pro (Figure 2C). Attempts to shorten
the extra aa in the cleaved products by eliminating two or
three of the amino acid residues from the MA/CA
site (Figure 1E), resulted in uncleavable variants
(TAT-Pro-HIV-MA/CA-3aa and TAT-Pro-HIV-MA/
CA-2aa; Figure 2D).
Enzymatic activity assay for cleaved TAT-fused
maize RIP
To compare the N-glycosidase activity of the maize RIP
variants before and after the removal of the internal inacti-
vation region, HIV-1 protease-cleaved TAT-Pro-
HIV-MA/CA and TAT-Pro-HIV-p2/NC were puriﬁed by
gel ﬁltration chromatography and incubated with mouse
macrophages (J774A.1) for 6h. Afterwards, total RNA
was isolated for cDNA synthesis. The amount of rRNA
depurination was detected quantitatively in a site-speciﬁc
manner using primers that targeted the altered sequences
by qRT-PCR (28). Two published primer sets were used
for the ampliﬁcation of the total 28S rRNA and the
depurinated site caused by the N-glycosidase activity, re-
spectively (28). The eﬃciency of the primer sets was tested
using serial dilution of cDNA synthesized from the total
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Figure 2. Cleavage of TAT-fused maize RIP variants by HIV-1 protease. (A) Pro-HIV-MA/CA-16, Pro-HIV-MA/CA-20 and Pro-HIV-MA/CA
were cleaved by puriﬁed recombinant HIV-1 protease in vitro. Only Pro-HIV-MA/CA was completely cleaved. (B) TAT-Pro-HIV-MA/CA and
TAT-Pro-HIV-p2/NC were completely cleaved by HIV-1 protease in vitro. (C) HIV-1IIIB acutely infected C8166 cells (1 10
6) were incubated with
protein samples (0.4mg in a volume of 2ml) for 72h and immunoblotted with anti-MOD polyclonal antibodies speciﬁc for Pro-RIP and its cleavage
fragments ( 11 and 17kDa). (D) TAT-Pro-HIV-MA/CA-3aa and TAT-Pro-HIV-MA/CA-2aa were not cleaved by the same in vitro cleavage
reaction condition as in (A) and (B). Proteins were resolved by 15% SDS gel.
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linearity of the standard curves throughout the whole
range of serial dilution (r
2>0.99). The relative N-
glycosidase activity of TAT-MOD was about 5.5-fold
higher than TAT-Pro in mouse macrophage cells
(J774A.1; Figure 3B). Incubation with the cleaved
variants (cleaved TAT-Pro-HIV-MA/CA and cleaved
TAT-Pro-HIV-p2/NC) also resulted in a higher level of
depurinated rRNA than their uncleaved counterparts in
mouse macrophages (Figure 3B). This showed that
cleavage at the modiﬁed internal inactivation region by
HIV-1 protease restored the N-glycosidase activity.
Anti-HIV activity and N-glycosidase activity in HIV-1
infected cells
TAT-Pro and TAT-MOD were tested for the inhibition of
HIV replication in human T cells (C8166) infected with
two HIV-1 strains, HIV-1IIIB and an HIV-1 protease
inhibitor-resistant virus strain, (HIV-1 RF/V82F/I84V).
The latter strain is among the most commonly observed
in patients receiving protease inhibitor-containing
regimens (34,35). In HIV-1IIIB acutely infected C8166
cells, TAT-MOD showed concentration-dependent
inhibition of HIV replication. The 50% inhibition of syn-
cytium and p24 antigen production were at
0.62±0.08mM and 0.21±0.02mM (mean±SD in three
experiments), respectively (Table 1). In HIV-1 RF/V82F/
I84V acutely infected C8166 cells treated with TAT-MOD,
the 50% inhibition on syncytium and p24 antigen
production were at 0.37±0.05mM and 0.23±0.03mM
(mean±SD in three experiments), respectively.
TAT-Pro had a weaker inhibitory eﬀect on p24 anti-
gen production with IC50 1.20±0.25mM and
10.87±5.13mM in HIV-1IIIB and HIV-1 RF/V82F/I84V
acutely infected C8166 cells, respectively (Table 1 and
Supplementary Figure S1).
The anti-HIV activities of TAT-Pro-HIV-MA/CA
and TAT-Pro-HIV-p2/NC towards HIV-infected cells,
as well as the cytotoxic eﬀects towards uninfected cells
were examined. TAT-MOD and variants TAT-Pro-
HIV-MA/CA and TAT-Pro-HIV-p2/NC were potent in
inhibiting syncytium formation and p24 antigen produc-
tion in HIV-1IIIB and HIV-1 RF/V82F/I84V acutely
infected C8166 cells, whereas TAT-Pro possessed limited
inhibitory eﬀects (Table 1 and Supplementary Figure S1).
We found that the relative N-glycosidase activity of
TAT-MOD and the two variants were statistically compar-
able in HIV-1IIIB acutely infected C8166 (Figure 4), func-
tionally showing that the variants indeed went through an
activation process by endogenous HIV-1 protease in vivo.
In addition, a smaller amount of depurinated rRNA was
detected in uninfected C8166 cells treated with the variants
compared with TAT-MOD-treated cells (Figure 4).
Compared to TAT-MOD, the two variants were at least
5-fold less cytotoxic towards uninfected C8166 cells (Table
1). It suggested that this HIV-1 protease-activation mech-
anism enhanced the speciﬁcity of maize RIP towards
HIV-1 infected cells without compromising its N-
glycosidase activity.
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Figure 3. In vivo N-glycosidase activity of TAT-fused maize RIP and variants in mouse macrophage 28S rRNA (J774A.1). During ﬁrst-strand cDNA
synthesis, reverse transcriptase preferentially inserts an adenine at the site of depurination, resulting in a T to A transversion in sequencing reads.
N-glycosidase activity was determined by qPCR using primers that target the modiﬁed site. (A) qRT-PCR eﬃciency test for primer pairs. Signals
were obtained from the ampliﬁcation of serially diluted cDNA synthesized from the RNA of TAT-MOD treated cells. Filled square indicates total
28S rRNA and ﬁlled triangle indicates depurinated rRNA. The relative amount of cDNA template was plotted against the corresponding threshold
cycle number in log scale and ﬁtted with a linear regression model. SEMs were less than 1% of the corresponding CT values. (B) Relative
N-glycosidase activity of the TAT-fused maize RIP and variants. The relative N-glycosidase activity was calculated as the relative amount of
altered rRNA of sample-treated cells over the untreated cells and mean±SEM was calculated for the graphic presentation. Unpaired t-test was
performed for statistical analysis (n=6) (*P<0.05, **P<0.01).
6808 Nucleic Acids Research, 2010,Vol.38, No. 19DISCUSSION
We have recently solved the crystal and solution structures
of maize RIP (4,5). Except for the presence of an internal
inactivation region (Ala163-Asp189) on the surface of the
inactive precursor (Pro-RIP), the structures of Pro-RIP
and the one-chain active form (MOD) are highly similar,
indicating that the removal of the internal inactivation
region does not alter the global structure of maize RIP.
Several studies suggested that RIPs get access to the
ribosome by interacting with ribosomal proteins.
Trichosanthin has been shown to bind to ribosomal
proteins P0, P1 and P2 (36,37) and PAP to L3 (38,39).
It has also been reported that an a-helix at the
C-terminal domain of trichosanthin is responsible for
binding to P2 (36). By NMR chemical shift perturbation,
the P2 binding site of MOD has been mapped to the
N-terminal domain near the internal inactivation region,
which has four positively charged residues (K143–K146)
(5). The 25 aa internal inactivation region is believed to
sterically hinder the interaction of Pro-RIP with the
ribosome, as pull down assay has shown that Pro-RIP
cannot interact with rat ribosome and surface plasmon
resonance analysis showed that the dissociation constant
(KD) of Pro-RIP on puriﬁed rat ribosome is about 80-fold
higher than that of MOD (4).
With the knowledge of its role, we consider this inacti-
vation region a unique opportunity for targeting maize
RIP towards cells that express a speciﬁc protease for
cleaving the region. First, we established that replacing
the ﬁrst and last 10 amino acid residues of the internal
inactivation region with the 10 aa MA/CA or p2/NC
HIV-1 protease cleavage site (Figure 1C) resulted in
speciﬁc cleavage in vitro and in HIV-infected cells
(Figure 2A and B). Then we showed that the
TAT-fusion maize RIP variants exhibited higher inhibi-
tory eﬀects on p24 and syncytium formation in HIV-1
infected human C8166 and lower cytotoxic eﬀects in un-
infected cells. This demonstrated the possibility of using
the internal inactivation region of maize RIP as a switch
to activate the cytotoxin inside the target cells.
Studies of the MA/CA site using synthetic peptides sug-
gested that the residues occupying position P4 through P30
ﬂanking the scissile bonds were critical for speciﬁc and
eﬃcient cleavage (31,40). In our hands, however, variant
TAT-Pro-HIV-MA/CA-3aa which had the MA/CA sites
QNY/PIVQN (P3 to P50) and VSQNY/PIV (P5 to P30)
within a 25 aa sequence was not cleaved by HIV-1
protease in vitro, suggesting that the maize RIP sequence
immediately next to the protease sites also play a role in
the cleavage eﬃciency. Our data also suggested that the
length of the internal inactivation region is important for
the access of the HIV-1 protease. We found that restoring
the length to the naturally occurred internal region (25 aa)
resulted in eﬃcient HIV-1 protease cleavage. Variants
Pro-HIV-MA/CA-16 and Pro-HIV-MA/CA-20 with 16
and 20 aa internal inactivation region resulted in incom-
plete cleavage. In addition, diﬀerent HIV-1 protease
cleavage sites were cleaved in diﬀerent eﬃciency.
Compared to TAT-Pro-HIV-MA/CA, the higher inhibi-
tory activity of TAT-Pro-HIV-p2/NC on the replication
of HIV-1IIIB and HIV-1 RF/V84F/I84V (Table 1) is
probably due to a more eﬃcient in vivo cleavage of the
p2/NC site. It has been reported that after translation of
the HIV Gag precursor, initial cleavage occurred at the
p2/NC site which releases the RNA-binding NC protein
followed by an intermediate rate of cleavage at the
Table 1. Cytotoxicity of TAT-fused maize RIP variants in uninfected C8166 cells and inhibition of viral replication in HIV-1IIIB and HIV-1
RF/V82F/184V acutely infected C8166 cells
Uninfected C8166 HIV-1IIIB HIV-1 RF/V82F/I84V
Cytotoxicity
IC50 (mM)
Syncytial reduction
EC50 (mM)
p24 antigen reduction
EC50 (mM)
Syncytial reduction
EC50 (mM)
p24 antigen reduction
EC50 (mM)
TAT-Pro >15.93 5.69±0.96 1.20±0.25 6.02±0.67 10.87±5.13
TAT-MOD 3.27±0.26 0.62±0.08 0.21±0.02 0.37±0.05 0.23±0.03
TAT-Pro-HIV-p2/NC >15.87 0.55±0.05 0.19±0.02 0.33±0.01 0.15±0.03
TAT-Pro-HIV-MA/CA >15.78 1.27±0.15 0.57±0.17 1.71±0.13 1.30±0.33
The values are means±SD of three experiments (n=12).
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Figure 4. N-glycosidase activity of TAT-fused maize RIP and variants
in uninfected and HIV-1IIIB acutely infected human T lymphocyte
C8166 cells. Relative N-glycosidase activity was represented in linear
scale±SEM. Grey bars indicate HIV-1IIIB acutely infected C8166 cells,
while white bars indicate uninfected cells. Student t-test was used for
statistical analysis. ***P<0.001 versus TAT-MOD (n=6).
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to be p2/NC>p1/p6 MA/CA >CA/p2 in vitro (44).
Traditionally, N-glycosidase activity was assayed indir-
ectly by cell-free protein synthesis inhibition (45) or
directly by colorimetric detection of released adenine by
high performance liquid chromatography (HPLC) (46).
These methods suﬀer from low sensitivity and speciﬁcity,
and can only measure the in vitro N-glycosidase activity.
To achieve the high speciﬁcity and sensitivity required for
measuring the in vivo N-glycosidase activity of the
internalized maize RIP variants, the approach developed
by Melchior and Tolleson (28) was used to directly
measure the amount of depurinated rRNA. Our results
showed that the HIV-1 protease-activated variants had
an increased N-glycosidase activity compared to
their uncleaved counterparts in mouse macrophages
(Figure 3B). The maize RIP variants indeed possess cata-
lytic function in cells.
Our observation on the N-glycosidase activity of
TAT-MOD and TAT-Pro indicated that the removal of
the internal inactivation region increases the cytotoxicity
and anti-HIV activity of maize RIP (Table 1). The relative
N-glycosidase activity of TAT-MOD in HIV-1IIIB acutely
infected C8166 cells was about 5-fold higher than that of
the TAT-Pro and the results were consistent with the same
assay using mouse macrophage J774A.1 (Figures 3B and
4). Similarly, by comparing the EC50 of inhibition of p24
antigen production in HIV-1IIIB and HIV-1 RF/V82F/
I84V infected cells to TAT-Pro, the HIV-1 protease-
cleavable variants TAT-Pro-HIV-MA/CA and Pro-TAT-
Pro-HIV-p2/NC had 2- to 70-fold increase in the inhibitory
power while showing low cytotoxicity towards uninfected
C8166 cells. The data showed that compared to the
N-glycosidase activity, HIV replication is more sensitive
to the activated maize RIP variants. The next step for
generating a useful anti-HIV agent is to test the eﬀect of
these variants in an HIV-infected animal model and to
further improve their speciﬁcity and activity.
HIV-1 protease recognition sites have been employed by
other groups for the development of anti-HIV agents.
Serio and co-workers (47,48) demonstrated that the intro-
duction of an HIV protease cleavage site into the
C-terminus of Vpr inhibited the infectivity of HIV-1
provirus, because of the incomplete processing of the
polyprotein for viral maturation. Vocero-Akbani and
co-workers (49) modiﬁed a protease-activated caspase-3
by placing an HIV-1 protease cleavage site between its
p17 and p12 domains, where a 5 aa cleavage sequence
(IETD#S) was originally located between these domains
in the wild-type caspase-3 inactive precursor. This
modiﬁed caspase-3 induced apoptosis in Jurkat T cells
co-transduction with HIV protease (50). However, it is
not known whether the caspase was cleaved eﬃciently to
cause speciﬁc killing of the HIV-infected cells. Mitrea and
co-workers (51) inserted an HIV-1 protease recognition
sequence into a surface loop of barnase and conﬁrmed
that it can be cleaved by HIV protease in vitro.
However, there has been no study of its catalytic activity
in the cells.
Here, we have demonstrated that by incorporating the
HIV-1 protease cleavage sites to the internal inactivation
region, we can generate modiﬁed maize RIP with cytotox-
icity switched on by HIV-1 protease inside HIV-1 infected
cells. The variants had reduced cytotoxicity towards unin-
fected cells, but exhibited potent anti-HIV activity in
HIV-infected cells. The switching mechanism described
here provides a technology platform for creating
pathogen-speciﬁc cytotoxins. By incorporating diﬀerent
pathogen-speciﬁc protease target sites into the internal in-
activation region, maize RIP in principle can be activated
inside and destroy the concerned cells. Since diﬀerent RIPs
possess similar 3D structures, a modiﬁed inactivation
region may also be added to other RIPs for targeting
cells infected by HIV or other pathogens.
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